Humanized immunoglobulin reactive with B7 therewith

Details Humanized immunoglobulin reactive with B7 therewith Humanized immunoglobulin reactive with B7 therewith

2005-07-05

2005-07-05

Gambel, Phillip (Department: 1644)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Monoclonal antibody or fragment thereof

C424S130100, C424S133100, C424S141100, C424S143100, C424S144100, C424S173100, C435S069600, C435S325000, C435S326000, C435S328000, C435S332000, C435S343000, C435S343100, C435S346000, C435S252300, C435S320100, C435S455000, C530S387100, C530S387300, C530S388100, C530S388200, C530S388220, C530S388700, C530S388730, C536S023100, C536S023500, C536S023530

Reexamination Certificate

active

06913747

ABSTRACT:
The invention relates to humanized anti-B7-2 and anti-B7-1 antibodies, wherein each comprise a variable region of non-human origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune diseases, transplant rejection, inflammatory disorders and infectious diseases by administering humanized anti-B7-2 and/or anti-B7-1 antibodies.

REFERENCES:
patent: 5397703 (1995-03-01), de Boer et al.
patent: 5562903 (1996-10-01), Co et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5622701 (1997-04-01), Berg
patent: 5624821 (1997-04-01), Winter et al.
patent: 5648260 (1997-07-01), Winter et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5747034 (1998-05-01), de Boer et al.
patent: 5869050 (1999-02-01), de Boer et al.
patent: 5977318 (1999-11-01), Linsley et al.
patent: 6084067 (2000-07-01), Freeman et al.
patent: 6605279 (2003-08-01), Freeman et al.
patent: 6608180 (2003-08-01), Sharpe et al.
patent: 94/01547 (1994-01-01), None
patent: 95/03408 (1995-02-01), None
patent: WO 96/14865 (1996-05-01), None
patent: 98/19706 (1998-05-01), None
Genes IV, Lewin et al. Oxford University Press 1990 p. 810 Only.
Co, M.S. et al., “Chimeric and Humanized Antibodies with Specificity for the CD33 Antigen,”The J. of Immunology148(4):1149-1154 (1992).
Cole, M.S. et al., “Human IgG2 Variants of Chimeric Anti-CD3 Are Nonmitogenic to T cells,”The J. of Immunology159:3613-3621 (1997).
Daikh, D. et al., “The CD28-B7 costimulatory pathway and its role in autoimmune disease,”J. of Leukocyte Biol.62:156-162 (1997).
Ellison, J. and Hood, J., “Linkage and sequence homology of two human immunoglobulin in α heavy chain constant region genes,”Proc. Natl. Acad. Sci. USA79:1984-1988 (1982).
Engel, P. et al., “The B7-2 (B70) Costimulatory Molecule Expressed by Monocytes and Activated B Lymphocytes Is the CD86 Differentiation antigen,”Blood84(5):1402-1407 (1994).
Fleischer, J. et al., “Differential expression and function of CD80 (B7-1) and CD86 (B7-2) on human peripheral blood monocytes,”Immunology89:592-598 (1996).
Fujihara, M. et al., “Decreased Inducible Expression of CD80 and CD86 in Human Monocytes After Ultraviolet-B Irradiation: Its Involvement in Inactivation of Allogenecity,”Blood87(6):2386-2393 (1996).
Glaser, S.M. et al., “Dissection of the Combining Site in a Humanized Anti-Tac Antibody,”The J. of Immunology149(8): 2607-2614 (1992).
He, X.-Y. et al., “Humanization and Pharmacokinetics of a Monoclonal Antibody with Specificity for Both E- and P-Selectin,”The J. of Immunology160:1029-1035 (1998).
Jeannin, P. et al., “CD86 (B7-2) on Human B Cells,”The J. of Biol. Chemistry272(25):15613-15619 (1997).
Jefferis, R. and Lund, J., “Molecular characterization of IgG antibody effector sites,”Department of Immunol.,The Medical School, EDgbaston, Birmingham, pp. 115-126.
Levitt, M., “Molecular Dynamics of Native Protein,”J. Mol. Biol.168:595-620 (1983).
Morrisons, S.L. et al., “Complement activation and Fc receptor binding by IgG,” InProtein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man,M. Clark, eds. (England: Academic Titles), pp. 101-113 (1993).
Ohki, O. et al., “Functional CD86 (B7-2/B70) is predominantly expressed on Langerhans cells in atopic dermatitis,”British J. of Dermatology136:838-845 (1997).
Queen, C. et al., “A humanized antibody that binds to the interleukin 2 receptor,”Proc. Natl. Acad. Sci. USA86:1029-1033 (1989).
Reiser, H. and Schneeberger, E.E, “Expression and function of B7-1 and B7-2 in hapten-induced contact sensitivity,”Eur. J. Immunol. 26:880-885 (1996).
Reiser, H. and Stadecker, M.J., “Costimulatory B7 Molecules in the Pathogenesis of Infection and Autoimmune Disease,”Mechanisms of Disease335(18):1369-1377 (1996).
Rugtveit, J. et al., “Differential distribution of B7.1 (CD80) and B7.2 (CD86) costimulatory molecules on mucosal macrophage subsets in human inflammatory bowel disease (IBD),”Clin. Exp. Immunol.110:104-113 (1997).
Shalaby, M.R. et al., “Development of Humanized Bispecific Antibodies Reactive with Cytotoxic Lymphocytes and Tumor Cells Overexpressing the HER2 Protooncogene,”J. Exp. Med.175:217-225 (1992).
Tempest, P.R. et al., “Reshaping A Human Monoclonal Antibody to Inhibit Human Respiratory Syncytial Virus Infection In Vivo,”Bio/Technology9:266-271 (1991).
Townsend, S.E. and Allison, J.P., “Tumor Rejection After Direct Costimulation of CD8+T Cells by B7-Transfected Melanoma Cells,”Science259:368-369 (1993).
Yokozeki, H. et al., “Functional CD86 (B7-B70) on Cultured Human Langerhans Cells,”The Society for Investigative Dermatology, Inc.106:147-153 (1996).
Liu, Z-X., et al., “Increased Expression of Costimulatory Molecules on Peripheral Blood Monocytes in Patients With Crohn's Disease,”Scand J. Gastroenterol,32(12):1241-6 (1997).
Lisa A. Damico, et al., “Pharmacokinetics of IV Administered Murine Anti-Human B7.1 and Murine Anti-Human B7.2 in Cynomoglus Monkeys” Abstract, 17th Annual Scientific Meeting, Jan. 9, 1998.
Cromwell, M.A. and Goldman, S.J., Abstract: “The Human PBMC-Reconstituted Nod-Scid Mouse as Model of Superantigen-Induced Human T Cell Activation,” Experimental Biology 98 Meeting, Apr. 22, 1998.
Bluestone, J.A., “Costimulation and its role in organ transplantation,”Clinical Transplantation10:104-109 (1996).
Saltus, Richard, “Drug Allows Transplants of Mismatched Bone Marrow,”The Boston Globe,p. Al (Jun. 3, 1999).
Alegra, M-L. et al., Immunomodulation of transplant rejection using monoclonal antibodies and soluble receptors,Digestive Diseases and Sciences,40(1):58-64 (1995).
Bree, A.G. et al., “Humanized anti-B7-1 and anti-B7-2 antibodies prevent antigen specific induction of immunity in nonhuman primates immunized with tetanus toxoid and mumps virus vaccine,” Blood, 94(10) Suppl. 1 part 1, p. 439a (1999).
Hathcock, K.S. et al., “Role of the CD28-B7 costimulatory pathways in T cell-dependent B cell responses,”Advances in Immunology,62:131-166 (1996).
Lenschow, D.J. et al., “Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse,”J. Exp. Med.,181:1145-1155 (1995).
Lenschow, D.J. et al., “Inhibition of transplant rejection following treatment with anti-B7-2 and anti-B7-1 antibodies,”Transplantation,60:1171-1178 (1995).
Wettendorff, M. et al., “Generation of humanized Fab fragments of B7-24 mAb, an antibody with potential use in the prevention of graft rejection and development of graft-verses-host disease,”Med. Fac. Landbouwkundige en toegepaste biologische,60:2057-2063 (1995).
Azuma, M. et al., “B70 antigen is a second ligand for CTLA-2 and CD28,”Nature366:76-79 (1993).
Berzofsky, J.A. and Berkower, I.J., “Antigen-Antibody Interaction,” InFundamental Immunology,W.E. Paul eds. (NY: Raven Press), pp. 595-644 (1984).
Chen, L. et al., “Costimulation of Antitumor Immunity by the B7 Counter receptor for the T Lymphocyte Molecules CD28 and CTLA-4,”Cell71:1093-1102 (1992).

Affiliated with

Also associated with

Rating

Humanized immunoglobulin reactive with B7 therewith does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Humanized immunoglobulin reactive with B7 therewith, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Humanized immunoglobulin reactive with B7 therewith will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3396502